vs
合众银行（FSBC）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是合众银行的1.4倍（$65.1M vs $45.1M），合众银行净利率更高（41.3% vs 5.6%，领先35.7%），过去两年合众银行的营收复合增速更高（21.3% vs 5.1%）
合众银行是总部设在美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行。它旗下核心运营实体为美国银行全国协会，以US Bank品牌开展业务，提供银行、投资、抵押等金融服务。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
FSBC vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.4倍
$45.1M
净利率更高
FSBC
高出35.7%
5.6%
两年增速更快
FSBC
近两年复合增速
5.1%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $65.1M |
| 净利润 | $18.6M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | — | 12.2% |
| 净利率 | 41.3% | 5.6% |
| 营收同比 | — | 3.6% |
| 净利润同比 | 42.0% | 316.6% |
| 每股收益（稀释后） | $0.87 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBCMLAB
| Q1 26 | $45.1M | — | ||
| Q4 25 | $43.5M | $65.1M | ||
| Q3 25 | $41.3M | $60.7M | ||
| Q2 25 | $38.3M | $59.5M | ||
| Q1 25 | $35.3M | $62.1M | ||
| Q4 24 | $35.2M | $62.8M | ||
| Q3 24 | $31.8M | $57.8M | ||
| Q2 24 | $30.7M | $58.2M |
净利润FSBCMLAB
| Q1 26 | $18.6M | — | ||
| Q4 25 | $17.6M | $3.6M | ||
| Q3 25 | $16.3M | $2.5M | ||
| Q2 25 | $14.5M | $4.7M | ||
| Q1 25 | $13.1M | $-7.1M | ||
| Q4 24 | $13.3M | $-1.7M | ||
| Q3 24 | $10.9M | $3.4M | ||
| Q2 24 | $10.8M | $3.4M |
毛利率FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% |
营业利润率FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | 12.2% | ||
| Q3 25 | 53.8% | 7.8% | ||
| Q2 25 | 52.4% | 5.1% | ||
| Q1 25 | 52.0% | 2.4% | ||
| Q4 24 | 55.1% | 9.2% | ||
| Q3 24 | 48.0% | 6.1% | ||
| Q2 24 | 49.4% | 9.6% |
净利率FSBCMLAB
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.6% | 5.6% | ||
| Q3 25 | 39.6% | 4.1% | ||
| Q2 25 | 37.9% | 8.0% | ||
| Q1 25 | 37.1% | -11.4% | ||
| Q4 24 | 37.9% | -2.7% | ||
| Q3 24 | 34.4% | 5.9% | ||
| Q2 24 | 35.2% | 5.8% |
每股收益（稀释后）FSBCMLAB
| Q1 26 | $0.87 | — | ||
| Q4 25 | $0.83 | $0.65 | ||
| Q3 25 | $0.77 | $0.45 | ||
| Q2 25 | $0.68 | $0.85 | ||
| Q1 25 | $0.62 | $-1.30 | ||
| Q4 24 | $0.61 | $-0.31 | ||
| Q3 24 | $0.52 | $0.63 | ||
| Q2 24 | $0.51 | $0.62 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $644.4M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $458.5M | $186.7M |
| 总资产 | $5.0B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资FSBCMLAB
| Q1 26 | $644.4M | — | ||
| Q4 25 | — | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M |
总债务FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M |
股东权益FSBCMLAB
| Q1 26 | $458.5M | — | ||
| Q4 25 | $445.8M | $186.7M | ||
| Q3 25 | $431.3M | $178.5M | ||
| Q2 25 | $416.7M | $172.5M | ||
| Q1 25 | $406.5M | $159.8M | ||
| Q4 24 | $396.6M | $155.2M | ||
| Q3 24 | $389.9M | $161.5M | ||
| Q2 24 | $380.5M | $150.7M |
总资产FSBCMLAB
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.8B | $434.8M | ||
| Q3 25 | $4.6B | $430.4M | ||
| Q2 25 | $4.4B | $435.7M | ||
| Q1 25 | $4.2B | $433.3M | ||
| Q4 24 | $4.1B | $433.3M | ||
| Q3 24 | $3.9B | $454.1M | ||
| Q2 24 | $3.6B | $440.4M |
负债/权益比FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | $72.6M | $18.8M | ||
| Q3 25 | $18.8M | $8.2M | ||
| Q2 25 | $17.8M | $1.9M | ||
| Q1 25 | $15.5M | $12.7M | ||
| Q4 24 | $51.8M | $18.1M | ||
| Q3 24 | $17.5M | $5.3M | ||
| Q2 24 | $16.0M | $10.7M |
自由现金流FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | $71.4M | $18.0M | ||
| Q3 25 | $18.6M | $7.1M | ||
| Q2 25 | $17.5M | $884.0K | ||
| Q1 25 | $15.4M | $11.9M | ||
| Q4 24 | $51.2M | $17.3M | ||
| Q3 24 | $17.3M | $3.5M | ||
| Q2 24 | $15.8M | $9.9M |
自由现金流率FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | 164.3% | 27.7% | ||
| Q3 25 | 45.0% | 11.7% | ||
| Q2 25 | 45.8% | 1.5% | ||
| Q1 25 | 43.5% | 19.2% | ||
| Q4 24 | 145.5% | 27.6% | ||
| Q3 24 | 54.5% | 6.0% | ||
| Q2 24 | 51.6% | 16.9% |
资本支出强度FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 1.1% | ||
| Q3 25 | 0.5% | 1.8% | ||
| Q2 25 | 0.6% | 1.7% | ||
| Q1 25 | 0.3% | 1.2% | ||
| Q4 24 | 1.8% | 1.3% | ||
| Q3 24 | 0.7% | 3.1% | ||
| Q2 24 | 0.7% | 1.5% |
现金转化率FSBCMLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.12× | 5.17× | ||
| Q3 25 | 1.15× | 3.32× | ||
| Q2 25 | 1.23× | 0.40× | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | 1.60× | 1.54× | ||
| Q2 24 | 1.49× | 3.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBC
| Net Interest Income | $43.5M | 96% |
| Noninterest Income | $1.6M | 4% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
